Authorised representative (AR)

POTUS Medical (Hong Kong) Limited

Hong Kong MDACS·7 represented devices·4 applicants·Feb 25, 2022Sep 24, 2024
7
Total devices
4
Applicants
2022
First representation
2024
Most recent
AR overview
Bilingual authorised representative information and contact details
Authorised representative (EN)
POTUS Medical (Hong Kong) Limited
Phone
39552662
Timeline
First representation
Feb 25, 2022
Most recent
Sep 24, 2024
Risk class distribution
B
1
C
6
Applicant partnerships
Top manufacturers represented by this AR
Recent registrations
Latest 15 MDACS listings represented by POTUS Medical (Hong Kong) Limited
DeviceRisk classApplicantRegistered
IVD Test Reagent/Kits, Molecular Assay, Infection, Bacteria
体外诊断检测试剂/试剂盒, 分子检测, 感染, 细菌
CSeegene Inc.
Seegene Inc.
Sep 24, 2024
IVD Test Reagent/Kits, Immunoassay, Rapid Test, Bacteria, Legionella pneumophila, Antigen
体外诊断检测试剂/试剂盒, 免疫测定, 快速检测, 细菌, 嗜肺军团菌, 抗原
CSD Biosensor, Inc.
Sd Biosensor,Inc.
Sep 11, 2024
IVD Test Reagent/Kits, Immunoassay, Rapid Test, Bacteria, Streptococcus Pneumoniae, Antigen
体外诊断检测试剂/试剂盒, 免疫测定, 快速检测, 细菌, 肺炎链球菌, 抗原
CSD Biosensor, Inc.
Sd Biosensor,Inc.
Sep 11, 2024
IVD Test Reagent/Kits, Molecular Assay, Infection, Virus
体外诊断检测试剂/试剂盒、分子检测、感染、病毒
BSeegene Inc.
Seegene Inc.
Sep 09, 2024
IVD Test Reagent/Kits, Immunoassay, Rapid Test, Virus Severe Acute Respiratory Syndrome Coronavirus 2, Antigen
体外诊断 检测试剂/试剂盒、免疫测定、快速检测、病毒严重急性呼吸综合征冠状病毒2、抗原
CInTec PRODUCTS, INC.
英科新创(厦门)科技股份有限公司
Nov 03, 2022
IVD Test Reagent/Kits, Serology, Virus, Severe Acute Respiratory Syndrome Coronavirus 2, Antigen
体外诊断 检测试剂/试剂盒、血清学、病毒、严重急性呼吸综合征冠状病毒2、抗原
CAESKU.Diagnostics GmbH & Co. KG
Aesku.Diagnostics Gmbh&Co.Kg
May 16, 2022
IVD Test Reagent/Kits, Serology, Rapid Test, Virus, Severe Acute Respiratory Syndrome Coronavirus 2
体外诊断 检测试剂/试剂盒、血清学、快速检测、病毒、严重急性呼吸综合征冠状病毒 2
CAESKU.Diagnostics GmbH & Co. KG
Aesku.Diagnostics Gmbh&Co.Kg
Feb 25, 2022
About this profile

POTUS Medical (Hong Kong) Limited serves as the authorised representative for 7 medical devices in Hong Kong's MDACS framework. Analyse applicant partnerships, risk class exposure, and recent regulatory activity to understand their market footprint.